Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3511 AL 3525

Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study

Chris Min K, Dockendorf MF, Palcza J, Tseng J, Ma L, Stone JA, Kleijn HJ, Hodsman P, Masuo K, Tanen M, Troyer MD, van Vugt M, Forman MS.

Clin Pharmacol Ther. 2019 May;105(5):1234-1243. doi: 10.1002/cpt.1258. Epub 2019 Jan 18.

Sex differences of brain and their implications for personalized therapy

Rezzani R, Franco C, Rodella LF.

Pharmacol Res. 2019 Mar;141:429-442. doi: 10.1016/j.phrs.2019.01.030. Epub 2019 Jan 16.

Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimer's disease

Dalmasso MC, Brusco LI, Olivar N, Muchnik C, Hanses C, Milz E, Becker J, Heilmann-Heimbach S, Hoffmann P, Prestia FA, Galeano P, Avalos MSS, Martinez LE, Carulla ME, Azurmendi PJ, Liberczuk C, Fezza C, Sampaño M, Fierens M, Jemar G, Solis P, Medel N, Lisso J, Sevillano Z, Bosco P, Bossù P, Spalletta G, Galimberti D, Mancuso M, Nacmias B, Sorbi S, Mecocci P, Pilotto A, Caffarra P, Panza F, Bullido M, Clarimon J, Sánchez-Juan P, Coto E, Sanchez-Garcia F, Graff C, Ingelsson M, Bellenguez C, Castaño EM, Kairiyama C, Politis DG, Kochen S, Scaro H, Maier W, Jessen F, Mangone CA, Lambert JC, Morelli L, Ramirez A.

Transl Psychiatry. 2019 Jan 31;9(1):55. doi: 10.1038/s41398-019-0394-9.

Early life exposure to lead (Pb) and changes in DNA methylation: relevance to Alzheimer's disease

Bihaqi SW.

Rev Environ Health. 2019 Jun 26;34(2):187-195. doi: 10.1515/reveh-2018-0076.

Avoiding Alzheimer's disease: The important causative role of divalent copper ingestion

Brewer GJ.

Exp Biol Med (Maywood). 2019 Feb;244(2):114-119. doi: 10.1177/1535370219827907. Epub 2019 Feb 6.

Insights into the Potential Role of Mercury in Alzheimer's Disease

Bjørklund G, Tinkov AA, Dadar M, Rahman MM, Chirumbolo S, Skalny AV, Skalnaya MG, Haley BE, Ajsuvakova OP, Aaseth J.

J Mol Neurosci. 2019 Apr;67(4):511-533. doi: 10.1007/s12031-019-01274-3. Epub 2019 Mar 15.

A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer's Disease in Taiwan

Chang CC, Peng GS, Lai TJ, Li CH, Liu CK.

Adv Ther. 2019 Jun;36(6):1455-1464. doi: 10.1007/s12325-019-00939-0. Epub 2019 Apr 5.

Mediterranean and MIND Diets Containing Olive Biophenols Reduces the Prevalence of Alzheimer's Disease

Omar SH.

Int J Mol Sci. 2019 Jun 7;20(11):2797. doi: 10.3390/ijms20112797.

Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer's disease

Kalamägi J, Lavikainen P, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S, Tolppanen AM.

Ann Med. 2019 Aug-Sep;51(5-6):294-305. doi: 10.1080/07853890.2019.1642507. Epub 2019 Aug 12.

Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies

Ding J, Davis-Plourde KL, Sedaghat S, Tully PJ, Wang W, Phillips C, Pase MP, Himali JJ, Gwen Windham B, Griswold M, Gottesman R, Mosley TH, White L, Guðnason V, Debette S, Beiser AS, Seshadri S, Ikram MA, Meirelles O, Tzourio C, Launer LJ.

Lancet Neurol. 2020 Jan;19(1):61-70. doi: 10.1016/S1474-4422(19)30393-X. Epub 2019 Nov 6.

Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease

Vu M, Koponen M, Taipale H, Tanskanen A, Tiihonen J, Kettunen R, Hartikainen S, Tolppanen AM.

Int J Cardiol. 2020 Feb 1;300:221-225. doi: 10.1016/j.ijcard.2019.09.036. Epub 2019 Oct 30.

Attention Measures of Accuracy, Variability, and Fatigue Detect Early Response to Donepezil in Alzheimer's Disease: A Randomized, Double-blind, Placebo-Controlled Pilot Trial

Vila-Castelar C, Ly JJ, Kaplan L, Van Dyk K, Berger JT, Macina LO, Stewart JL, Foldi NS.

Arch Clin Neuropsychol. 2019 May 1;34(3):277-289. doi: 10.1093/arclin/acy032.

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Farlow MR, Thompson RE, Wei LJ, Tuchman AJ, Grenier E, Crockford D, Wilke S, Benison J, Alkon DL.

J Alzheimers Dis. 2019;67(2):555-570. doi: 10.3233/JAD-180759.

Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report

Supasitthumrong T, Bolea-Alamanac BM, Asmer S, Woo VL, Abdool PS, Davies SJC.

Br J Clin Pharmacol. 2019 Apr;85(4):690-703. doi: 10.1111/bcp.13844. Epub 2019 Feb 8.

Quantifying placebo responses in clinical evaluation of neuropsychiatric symptoms in Alzheimer's disease

Zhang N, Lv Y, Li H, Chen J, Li Y, Yin F, Li L, Zheng Q.

Eur J Clin Pharmacol. 2019 Apr;75(4):497-509. doi: 10.1007/s00228-018-02620-x. Epub 2019 Jan 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias